US Patent

US8846628 — Oral formulations of cytidine analogs and methods of use thereof

Method of Use · Assigned to Celgene Corp · Expires 2030-06-03 · 4y remaining

Vulnerability score 68/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects oral formulations of cytidine analogs, such as 5-azacytidine or decitabine, for treating diseases and disorders.

USPTO Abstract

The present disclosure provides pharmaceutical compositions comprising cytidine analogs, for example, 5-azacytidine or decitabine, for oral administration, wherein the compositions release the cytidine analog, for example, 5-azacytidine or decitabine, substantially in the stomach. Also provided are methods of treating diseases and disorders using the oral formulations provided herein.

Drugs covered by this patent

Vidaza (azacitidine) · Bristol-Myers Squibb

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2950`	—	Vidaza
`U-2950`	—	Vidaza

Patent Metadata

Patent number: US8846628
Jurisdiction: US
Classification: Method of Use
Expires: 2030-06-03
Drug substance claim: No
Drug product claim: Yes
Assignee: Celgene Corp
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.